Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing

Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma

(2018) Amr Menshawy et al.   MELANOMA RESEARCH

Talimogene laherparepvec: First in class oncolytic virotherapy

(2018) Robert M. Conry et al.   Human Vaccines & Immunotherapeutics

Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

(2018) Lillian Sun et al.   Journal for ImmunoTherapy of Cancer

Virotherapy Research in Germany: From Engineering to Translation

(2017) Guy Ungerechts et al.   HUMAN GENE THERAPY

Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial

(2017) Karsten Geletneky et al.   MOLECULAR THERAPY

Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity

(2017) Assia Angelova et al.   Viruses-Basel

Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes

(2017) Bernd Heinrich et al.   OncoTargets and Therapy

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

(2015) Sonja Kleffel et al.   CELL

Oncolytic Virus Immunotherapy for Melanoma

(2015) Neal Dharmadhikari et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy

(2015) Anna Śledzińska et al.   Molecular Oncology

Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy

(2015) Youra Kim et al.   Viruses-Basel

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

(2015) R. Winograd et al.   Cancer Immunology Research

Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer

(2014) A. L. Angelova et al.   JOURNAL OF VIROLOGY

Oncolytic Virotherapy as Emerging Immunotherapeutic Modality: Potential of Parvovirus H-1

(2014) Markus Moehler et al.   Frontiers in Oncology

The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production

(2013) Stefania Laurent et al.   Journal of Translational Medicine

Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells

(2013) Bernd Heinrich et al.   OncoTargets and Therapy

Cellular Constituents of Immune Escape within the Tumor Microenvironment

(2012) S. P. Kerkar et al.   CANCER RESEARCH

Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1

(2012) Maike Sieben et al.   INTERNATIONAL JOURNAL OF CANCER

Activation of a Helper and Not Regulatory Human CD4+ T Cell Response by Oncolytic H-1 Parvovirus

(2012) Olivier Moralès et al.   PLoS One

Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1

(2011) Markus Moehler et al.   BMC CANCER

CTLA-4 is expressed by human monocyte—derived dendritic cells and regulates their functions

(2010) Stefania Laurent et al.   HUMAN IMMUNOLOGY

Dendritic Cells Induce Regulatory T Cell Proliferation through Antigen-Dependent and -Independent Interactions

(2010) T. Zou et al.   JOURNAL OF IMMUNOLOGY

Improvement of Gemcitabine-Based Therapy of Pancreatic Carcinoma by Means of Oncolytic Parvovirus H-1PV

(2009) A. L. Angelova et al.   CLINICAL CANCER RESEARCH

CTLA-4 trafficking and surface expression

(2008) Elke Valk et al.   TRENDS IN IMMUNOLOGY